Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Carcinoma

Carcinoma, Basal Cell

Skin Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Basal Cell

AIV001

To evaluate safety and efficacy of AIV001 treatment on low-risk basal cell carcinoma.

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

An Exploratory Study to Evaluate the Safety and Efficacy of AIV001 Intradermally Administered in Subjects With Biopsy-confirmed Basal Cell Carcinoma

Number of participants cleared of basal cell carcinoma within study duration

AiViva BioPharma, Inc.

Symptoms and General Pathology

Behaviors and Mental Disorders

Carcinoma, Squamous Cell

Facies

Keratosis, Actinic

Keratosis

Quality of Life

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Imiquimod

Immunomodulating Agents

Immunologic Factors

Adjuvants, Immunologic

Interferons

Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.

The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.

5% Imiquimod cream

Placebo Vehicle Control Cream

Kel G Morin

Martin A Weinstock, MD

Martin A. Weinstock, MD

This is an intent-to-treat, split-plot design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.

Basal Cell Carcinoma (BCC) is the most common cancer in the United States. It afflicts 2 to 3 million Americans each year, more than all non-skin cancers combined. Notably, US active duty military and Veterans are at higher risk for developing BCC, with at least 49,000 Veterans treated for the disease in 2010. BCC usually occurs on the face and hence can result in high morbidity and disfigurement with substantial associated expense both in the overall population (estimated at $3 billion in 2013), and among Veterans (estimated at $86 million in 2012) served by Veterans Health Administration (VHA). Morbidity and disfigurement are particularly important due to their impact on key facial structures (e.g. eyelids, nose, etc). After BCC diagnosis, subsequent monitoring for BCC (ex. return specialist visits for dermatologic examinations) and treatments following diagnosis (surgeries most commonly, but also radiation therapy or chemotherapy) significantly contribute to healthcare costs. This large incidence, morbidity, and cost could potentially be minimized through preventative measures, but currently there are no treatment options for preventing BCC.

The primary goal of this study is to investigate the efficacy of topical Imiquimod (IMQ) for the prevention of BCC. IMQ, a topical immunostimulatory medication with a very low rate of side effects, is potentially capable of meeting this need. IMQ is already FDA approved as a safe and effective treatment for superficial BCC, as well as for actinic keratosis and nodular BCC. The investigators have reason to suspect that IMQ may also be able to prevent the occurrence of BCC or to destroy clinically-unrecognized precursors of BCC, thereby reducing the risk of BCC development.

CSP #2019 is an intent-to-treat, split-plot design, multicenter randomized trial with two levels of randomization. The patient level of randomization is the primary intervention: a double-blind comparison of IMQ vs. placebo cream for preventing BCC on the face at one year and over 3 years after therapy. VA has developed an automated text message service application called Annie that can send automated treatment reminders to Veterans if they register/enroll in Annie and consent to receive Annie messages. In the center level of randomization, 9 of 17 participating VA centers will be randomly assigned to offer the participants daily study treatment reminders via the Annie app. The remaining centers will not offer daily reminders via Annie. Participants in each center will be randomly allocated (1:1) to either topical IMQ or placebo (vehicle control cream). Study participants, staff and study dermatologists will not know which treatment the participant receives. Participants will apply IMQ or placebo cream to the face daily at bedtime for a total of 12 weeks. In-person visits will occur at weeks 6 and 12 during treatment, and at months 6, 12, 18, 24, 30, and 36 during active follow-up to assess study outcomes. Full skin exams will be performed and other outcome data collected at every scheduled in-person visit. Telephone interviews will occur every week through week 13 (other than weeks 6 and 12, due to an in-person visit), as well as at months 9, 15, 21, 27, and 33. Follow-up will include 3 years of active follow-up with participants, followed by 1 year of passive follow-up during which study outcome information will only be captured from medical records.

Basal Cell Carcinoma Chemoprevention Trial

CSP #2019 - Basal Cell Carcinoma Chemoprevention Trial (B3C)

After the main results of this study have been published, de-identified data from the study may be shared with other VA investigators, other Federal health agencies, or academic institutions for additional analyses provided this use has been approved by CSP, the appropriate VA oversight committee(s), and there is an agreement in place that defines the limits of this use.

With the participant's approval and as approved by local Institutional Review Boards (IRBs), deidentified study data will be moved into a data repository where other CSP studies are maintained after the study has ended. This data could be used for future research on the conditions, characteristics, complications, and treatments covered in the proposed work.

Skin exams will occur at baseline and at 6-month intervals after study randomization. Diagnosis of a new BCC will be ascertained by a biopsy under local anesthesia in an outpatient setting, as is the standard of care. Every biopsy performed on the face of a participant during the trial will be processed per standard clinical operating procedures, as determined by their blinded clinician for the purposes of patient management. The biopsy will be sent for reading by a blinded central dermatopathologist with known high reliability (intra-rater and inter-rater with two other board-certified dermatopathologists) for diagnosing BCC. This central dermatopathologist diagnosis will be used for study purposes. Skin cancers diagnosed outside of the VA, and associated surgeries, will be systematically sought in all participants by participant interview and review of medical records to ensure that the outcome measure is complete.

Basal Cell Carcinoma (BCC) free time to a new BCC on the face over 3 years is defined as the time in years from treatment randomization to the first occurrence of a new BCC on the face. Participants who do not develop a new BCC on the face by 3 years will be considered censored observations. Skin exams will occur at baseline and at 6-month intervals after study randomization.

Diagnosis of a new SCC will be ascertained by a biopsy under local anesthesia in an outpatient setting, as is the standard of care. Every biopsy performed on the face of a participant during the trial will be processed per standard clinical operating procedures, as determined by their blinded clinician for the purposes of patient management, and the biopsy will also be sent for reading by a blinded central dermatopathologist with known high reliability (intra-rater and inter-rater with two other board-certified dermatopathologists) for diagnosing SCC. This central dermatopathologist diagnosis will be used for study purposes. Skin cancers diagnosed outside of the VA, and associated surgeries, will be systematically sought in all participants by participant interview and review of medical records to ensure that the outcome measure is complete.

Squamous Cell Carcinoma (SCC) free time to a new SCC on the face over 3 years is defined as the time in years from treatment randomization to the first occurrence of a new SCC on the face. Participants who do not develop a new SCC on the face by 3 years will be considered censored observations.

AK reduction persistence over time will be assessed using total AK counts (on the face only) evaluated at in-person visits at weeks 6 and 12 and months 6, 12, 18, 24, 30, and 36, and will be analyzed as a repeated measures outcome.

The proportion of participants with any Actinic Keratosis (AK) biopsies on the face from the start of study treatment up to 1 year. Data collection regarding AK biopsies on the face will be assessed at weeks 6 and 12 during treatment, and months 6, 9, and 12 during active follow-up.

The proportion of participants with any Actinic Keratosis (AK) cryotherapeutic treatments on the face from the start of study treatment up to 1 year. Data collection regarding AK cryotherapeutic treatments on the face will be assessed at weeks 6 and 12 during treatment, and months 6, 9, and 12 during active follow-up.

The proportion of participants with any Actinic Keratosis (AK) treatments on the face from the start of study treatment up to 1 year. Data collection regarding AK treatments on the face will be assessed at weeks 6 and 12 during treatment, and months 6, 9, and 12 during active follow-up. AK treatment will include biopsies, cryotherapeutic treatments, or any other non-cryotherapeutic AK treatments.

High-risk subsites for BCC on the face include the ear, eye (including eyebrows), and nose areas.

Higher risk subsites for BCC on the face include the ear, eye (including eyebrows), and nose areas.

Higher risk histologic subtypes include infiltrative/morpheaform and nodular/infiltrative BCCs.

The proportion of participants who have experienced a high severity Basal Cell Carcinoma (BCC) at 1 year will be determined. To be considered a high severity (i.e. high morbidity) BCC, the tumor must have at least one of the following features:

i.AJCC stage 3 BCC ii.BCC requiring postoperative adjuvant radiation iii.BCC requiring multidisciplinary surgery (i.e. oculoplastics, ENT, or neurosurgery, with or without concomitant Mohs micrographic surgery) iv.BCC requiring systemic treatment

The proportion of participants who have experienced a high severity Basal Cell Carcinoma (BCC) at 3 years will be determined. To be considered a high severity (i.e. high morbidity) BCC, the tumor must have at least one of the following features:

i.AJCC stage 3 BCC ii.BCC requiring postoperative adjuvant radiation iii.BCC requiring multidisciplinary surgery (i.e. oculoplastics, ENT, or neurosurgery, with or without concomitant Mohs micrographic surgery) iv.BCC requiring systemic treatment

The proportion of participants who have experienced a high or moderate severity Basal Cell Carcinoma (BCC) at 1 year will be determined. To be considered a high severity (i.e. high morbidity) BCC, the tumor must have at least one of the following features:

i.AJCC stage 3 BCC ii.BCC requiring postoperative adjuvant radiation iii.BCC requiring multidisciplinary surgery (i.e. oculoplastics, ENT, or neurosurgery, with or without concomitant Mohs micrographic surgery) iv.BCC requiring systemic treatment

To be considered a moderate severity (i.e. moderate morbidity) BCC, the tumor must require surgical removal, which may include removal with Mohs micrographic surgery, but not meet the criteria for high severity. To be included in mild severity/morbidity, the tumor must not require surgical intervention.

The proportion of participants who have experienced a high or moderate severity Basal Cell Carcinoma (BCC) at 3 years will be determined. To be considered a high severity (i.e. high morbidity) BCC, the tumor must have at least one of the following features:

i.AJCC stage 3 BCC ii.BCC requiring postoperative adjuvant radiation iii.BCC requiring multidisciplinary surgery (i.e. oculoplastics, ENT, or neurosurgery, with or without concomitant Mohs micrographic surgery) iv.BCC requiring systemic treatment

To be considered a moderate severity (i.e. moderate morbidity) BCC, the tumor must require surgical removal, which may include removal with Mohs micrographic surgery, but not meet the criteria for high severity. To be included in mild severity/morbidity, the tumor must not require surgical intervention.

The proportion of participants with redness on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with burning on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with soreness/tenderness on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with crusting/erosions on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with scaling/flaking on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with swelling on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with itching on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with pain on the face during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with fatigue during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with fever during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with headache during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

The proportion of participants with flu-like symptoms during the 12 weeks of the active treatment period or the week following the end of active treatment (week 13).

Tolerability of treatment side effects will be assessed weekly during active study treatment (weeks 1-13) as a binary response (yes/no).

The Skindex-16 is a 16-item scale to measure the effects of skin disease on a patient's quality of life. All item responses are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex scores are reported as three scale scores corresponding to the following three domains or subscales: Symptom, Emotional, Functional. A scale score is the average of a patient's responses to items in a given domain. Higher domain scale scores represent worse quality of life.

The Functional Assessment of Cancer Therapy - General (FACT-G) is a 27-item questionnaire designed to measure four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being. Only the 7-item Physical Well-being subscale is being used in this study. The Physical Well-being score range is 0-28, and the higher score, the better the quality of life.

The proportion of participants indicating acceptability of their assigned treatment cream at 12 weeks. Acceptability will be assessed by asking participants at 12 weeks whether they would be willing to use the cream they received again in the future if the cream is determined to be effective in reducing their risk of developing future skin cancer on the face.

Medication compliance will be defined as a binary outcome (\>=80% compliance vs \<80% compliance). Individuals applying 67 or more of the expect 84 doses (67/84=80% with rounding) will be considered \>=80% medication compliant, while those applying \<67 doses will be considered \<80% compliant.

Medication compliance status will be defined as a binary outcome (\>=80% compliance vs \<80% compliance). Individuals applying 67 or more of the expect 84 doses (67/84=80% with rounding) will be considered \>=80% medication compliant, while those applying \<67 doses will be considered \<80% compliant.

The US Department of Veterans Affairs has developed an automated text message service application called Annie that can send automated treatment reminders to Veterans if they register/enroll in Annie and consent to receive Annie text messages. Nine of the 17 study sites will be randomly selected to offer the Annie application to their study participants. The medication compliance status during the 12 weeks of active treatment (as defined above) will be presented for the 9 study sites offering the Annie app and the 8 sites not offering it (irrespective of study treatment group).

Medication compliance status will be defined as a binary outcome (\>=80% compliance vs \<80% compliance). Individuals applying 67 or more of the expect 84 doses (67/84=80% with rounding) will be considered \>=80% medication compliant, while those applying \<67 doses will be considered \<80% compliant.

Veterans Affairs has developed an application called Annie that can send text treatment reminders to Veterans if they enroll in Annie. Nine of the 17 sites will be randomly selected to offer Annie to their participants. Annie use is voluntary and not required for participation. Among the sites offering Annie, we will ask participants whether they received any treatment reminders via Annie \& a categorical Annie use variable will be created. Only for the 9 sites offering Annie, the medication compliance status (as defined above) will be presented for the participants that used Annie and those that didn't.

Skin exams will occur at baseline \& 6 months after randomization. Diagnosis of a new facial BCC will be via biopsy under local anesthesia in an outpatient setting (standard of care). Every facial biopsy will be processed per standard operating procedures, as determined by the blinded clinician for the purposes of patient management. Biopsies will be read by blinded central dermatopathologist with known high reliability (intra-rater \& inter-rater with 2 board-certified dermatopathologists) for diagnosing BCC. Central dermatopathologist diagnosis will be used for study purposes. BCC diagnosed outside VA \& surgeries will be collected by participant interview and review of medical records to ensure the outcome measure is complete. Medication compliance will be defined as a binary outcome (\>=80% vs \<80%). Individuals applying 67 or more of the expect 84 doses (67/84=80% with rounding) will be considered \>=80% compliant, while those applying \<67 doses will be considered \<80% compliant.

Basal Cell Carcinoma (BCC) free time to a new BCC on the face over 3 years is defined as the time in years from treatment randomization to the first occurrence of a new BCC on the face. Participants who do not develop a new BCC on the face by 3 years will be considered censored observations. Skin exams will occur at baseline and at 6-month intervals after study randomization.

Medication compliance status will be defined as a binary outcome (\>=80% compliance vs \<80% compliance). Individuals applying 67 or more of the expect 84 doses (67/84=80% with rounding) will be considered \>=80% medication compliant, while those applying \<67 doses will be considered \<80% compliant.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma	NCT04470726	Superficial Bas... Nodular Basal C...	AIV001	18 Years - 80 Years	AiViva BioPharma, Inc.
Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma	NCT04470726	Superficial Bas... Nodular Basal C...	AIV001	18 Years - 80 Years	AiViva BioPharma, Inc.
Basal Cell Carcinoma Chemoprevention Trial	NCT05212246	Basal Cell Carc...	5% Imiquimod cr... Placebo Vehicle...	18 Years -	VA Office of Research and Development

Spots Global Cancer Trial Database for keratinocyte carcinoma